New drug aims to halt kidney damage in IgA nephropathy
NCT ID NCT06797518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests iptacopan, an oral drug, in 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to see if the drug reduces signs of inflammation and damage over 9 months. The goal is to understand if iptacopan can slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iptacopan (oral capsule)
What this could lead to
If successful, this could point toward a treatment that slows kidney damage in IgA nephropathy patients.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The main focus is on biomarker changes, not long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
CaRe Research
RECRUITINGChubbuck, Idaho, 83202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Central Florida Kidney Specialists
RECRUITINGOrlando, Florida, 32806, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
DaVita Clinical Research
RECRUITINGLas Vegas, Nevada, 89146, United States
Contact Email: •••••@•••••
Contact
-
Georgia Nephrology Research Inst
RECRUITINGLawrenceville, Georgia, 30046, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGCABA, Buenos Aires, 1280, Argentina
-
Novartis Investigative Site
RECRUITINGCABA, Buenos Aires, 1425, Argentina
-
Novartis Investigative Site
RECRUITINGCórdoba, Córdoba Province, 5000, Argentina
-
Novartis Investigative Site
RECRUITINGAshdod, 7747629, Israel
-
Novartis Investigative Site
RECRUITINGHadera, 3820302, Israel
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGNahariya, 2210001, Israel
-
Novartis Investigative Site
RECRUITINGKuala Lumpur, Selangor, 43000, Malaysia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
-
OSU Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prolato Clinical Research Center
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCLA Medical Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Email: •••••@•••••
Contact
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact